Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial

[Background] Everolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The SEQTOR trial aimed to assess the optimal treatment sequence.

Detalhes bibliográficos

Autores:	Capdevila, Jaume, Tafuto, Salvatore, Krogh, Merete, Teulé, Alex, García-Carbonero, Rocío, Klümpen, Heinz-Josef, Cremer, Birgit, Sevilla, Isabel, Eriksson, Barbro, Tabaksblat, Elizaveta, Metgès, Jean Philippe, Reed, N. S., Schrader, J., Navarro, Valentín, Valentí, Vicente, Hernando, J., Colao, A .M., Vestermark, L., Carnaghi, C., Knigge, U. P., Jiménez-Fonseca, Paula, Benavent Viñuales, Marta, de Vos-Geelen, J., Venerito, Marino, Von Werder, A., Jann, H, Rinke, Anja, Smith, D., Hörsch, D., Starling, N., Ruszniewski, P., Baudin, Eric, Caroli-Bosc, F-X, Manzano, José Luis, Martín, Marta, Scarpa, Aldo, Lawlor, Rita T., Ragulan, Chanthirika, Ps, Hari, Sadanandam, Anguraj, Carmona-Bayonas, Alberto, Salazar, Ramón
Formato:	artículo
Estado:	Versión publicada
Fecha de publicación:	2025
País:	España
Recursos:	Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:	DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:	oai:digital.csic.es:10261/413253
Acesso em linha:	http://hdl.handle.net/10261/413253 https://api.elsevier.com/content/abstract/scopus_id/105023675073
Access Level:	acceso abierto
Palavra-chave:	5-Fluorouracil Advanced pancreatic neuroendocrine neoplasm Everolimus PanNET Sequential strategy Streptozotocin